Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
241. |
ECCT/18/10/03 | UMBIFLOW Prevalence and outcomes of abnormal continuous wave Doppler flow indices in unselected obstetric populations in low- and middle-income countries: The Umbiflow International Study. |
Principal Investigator(s) 1. Prof Zahida Parveen Qureshi Site(s) in Kenya 1. Mbagathi District Hospital (Nairobi City county) 2. St. Mary\'s Hospital (Nairobi City county) 3. Kenyatta National Hospital (Nairobi City county) |
View |
242. |
ECCT/14/06/01 | ACTG -5279 Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Dr. Kevin N/A Cain Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) 2. Moi University Clinical Research Center CRS ()12601 (Uasin Gishu county) |
View |
243. |
ECCT/20/12/01 | KU ‘TIBA VENT\' Phase I/II, Open Label Randomized Controlled Trial Evaluating Safety of 'KU TIBA VENT" For Mechanical Ventilation in Patients With Respiratory Failure During Weaning Phase Abstract KU TIBA VENT There is ongoing pandemic caused by SARS-Cov-2, commonly referred to us COVID-19 that started in China in December 2019. The patients develop acute respiratory failure requiring machine assisted breathing. However, due to the huge numbers affected patients, the demand for mechanical ventilators outstrip supply worldwide. This is especially so in Kenya with poor health systems. In response to the increased demand for mechanical ventilators, a group of students plus their lecturer mentors at Kenyatta University responded by designing and producing a ‘TIBA VENT” from locally available materials. The design and production processes have been evaluated by the Kenya Bureau of Standards and found to be in conformity with the countries standards. We have designed a protocol to guide clinical validation before registration by Pharmacy and Poisons Board as part of requirement for commercialization. The main objective of this clinical validation is to assess the dependability and reliability of the device when connected to patients in the intensive care Unit. The secondary end points are to assess the functionality of the control variables, the trigger settings as well as user concerns to facilitate design modifications before roll out. The clinical validation will be done at Kenyatta University Teaching, Research and Referral Hospital (KUTRRH). This is a phase II of study with expected duration of 14 days and enrolling at least 4 patients. The sponsor for the study is the Kenyatta University. The information obtained will assist in design modifications before commercialization. This is an example of homegrown innovation. |
Principal Investigator(s) 1. Gordon Oluoch Ogweno Site(s) in Kenya Kenyatta University Teaching Research and Referral Hospital (KUTRRH) |
View |
244. |
ECCT/20/09/01 | PrEP in Pharmacy - PILOT STUDY Pharmacy delivery to expand the reach of PrEP in Kenya: Pilot study |
Principal Investigator(s) 1. Kenneth Kairu Ngure Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
View |
245. |
ECCT/23/02/05 | Pharmacy PrEP cRCT Pharmacy delivery to expand the reach of PrEP in Kenya: cluster-randomized control trial |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Kenneth Ngure Site(s) in Kenya 1. Kenya Medical Research Institute, Center for Microbiology Research, Research Care and Training Programme (KEMRI-CMR-RCTP) research center (Kisumu county) 2. Kenya Medical Research Institute, Center for Clinical Research, Partners in Health and Research Development (KEMRI-CCR-PHRD) research center (Kiambu county) |
View |